TRT + peptides, graded honestly
If you are already on testosterone replacement and thinking about adding peptides, almost everything written for you was written by someone who sells the peptide. This page is not. We sell no compounds — so we can tell you which pairings actually have human data behind them, which are practitioner consensus, and which are pure experiment.
Every pairing below is tagged with the same evidence lane it carries in our library. A vendor cannot pay to move a compound up a lane. Read why we have no incentive to oversell a stack, and how the lanes are assigned.
The one thing most TRT-stack guides skip
TRT acts on the hypothalamic-pituitary-testicular axis. Most of the peptides people add — GH secretagogues, recovery peptides, GLP-1 agonists — act on entirely different systems. That is good news: there are very few direct drug interactions between testosterone and these peptides.
The real risk is not interaction, it is unmonitored compounding. A GH-axis peptide on top of TRT means two things nudging IGF-1, glucose, and body composition at once. If you only track your testosterone markers, you will miss the half of the picture the peptide is moving. The fix is bloodwork, not avoidance.
Pairings, by evidence lane
BPC-157
ExperimentalGoal: Connective-tissue / injury recovery alongside TRT-driven training volume
TRT tends to increase training output, which increases tendon and joint load. BPC-157 is the most-discussed recovery peptide for that gap. Human trial data is absent — it sits in the Experimental lane for a reason — but it does not act on the HPTA, so it carries no direct conflict with a testosterone protocol.
Watch: No specific TRT-interaction bloodwork. Source quality is the dominant risk; recovery claims are anecdotal, not clinical.
CJC-1295 / Ipamorelin
ExpertGoal: Add a GH/IGF-1 axis on top of the androgen axis for body recomposition and sleep
This is the most common GH-secretagogue pairing requested by TRT users. It raises endogenous GH pulses rather than replacing testosterone, so the two axes are additive rather than competing. Practitioner protocols converge here, which is why it sits in the Expert lane — but it is not backed by the same trial weight as TRT itself.
Watch: IGF-1 (do not let it run unmonitored), fasting glucose / HbA1c (GH secretagogues can blunt insulin sensitivity), and water retention. Stack the GH effect on top of TRT's, do not assume they cancel.
Tesamorelin
ClinicalGoal: Visceral-fat reduction in the TRT user carrying central adiposity
Tesamorelin is FDA-approved for HIV-associated lipodystrophy and has human trial data for visceral-fat reduction — which is why it earns the Clinical lane where most GH peptides do not. For a TRT user whose lab work shows high visceral fat, it is the better-evidenced GH-axis choice than the CJC/Ipamorelin pairing.
Watch: IGF-1 and glucose, same as any GH-axis agent. It is the most evidence-backed option here, not a risk-free one.
Tirzepatide / Semaglutide
ClinicalGoal: Fat loss when TRT alone has not moved body composition
GLP-1 (and GLP-1/GIP) agonists act on appetite and glycemia, fully independent of the androgen axis. For a TRT user who is recomposition-stalled, this is the most clinically-grounded add-on of any on this page. See our GLP-1 head-to-head for the dose and side-effect contrast.
Watch: GI tolerance during titration; lean-mass preservation (pair with adequate protein and resistance training, which TRT already supports). Neither is safe in pregnancy and neither interacts with testosterone directly.
Sermorelin
ExpertGoal: A gentler GH-axis nudge for the cautious TRT user
Sermorelin is a shorter-acting GHRH analog often chosen by TRT users who want a milder GH-axis effect than CJC-1295. Practitioner use is well established (Expert lane); it shares the GH-axis monitoring profile but at a lower intensity.
Watch: IGF-1 and glucose. Lower potency than CJC-1295 means a smaller effect to monitor, not a free pass.
Bloodwork the stacker should actually run
You already pull labs for TRT. Adding peptides means adding a few markers — and not dropping the TRT ones. This is the panel that lets you tell which compound is doing what.
Total & free testosterone, estradiol (E2)
Your TRT baseline. None of the peptides below should move these — if they appear to, something else changed. Track them so you can attribute effects correctly.
Hematocrit & hemoglobin
TRT can raise hematocrit on its own. Adding training volume (which recovery peptides encourage) does not change the need to watch it. This is a TRT marker, not a peptide one, but stackers forget it.
IGF-1
The single most important marker once any GH-axis peptide (CJC-1295, ipamorelin, sermorelin, tesamorelin) enters the stack. Running a GH secretagogue without checking IGF-1 is the most common unmonitored risk in this segment.
Fasting glucose / HbA1c
GH-axis peptides can reduce insulin sensitivity; GLP-1 agonists improve glycemia. If you stack both, these markers tell you the net direction.
Lipid panel
Both TRT and body-composition changes move lipids. A shared baseline lets you separate the testosterone effect from the peptide effect.
Build the stack with the math done for you
DoseCraft tracks every compound in your stack on one timeline, flags GH-axis and glucose interactions, and runs the reconstitution math so a TRT-plus-peptide protocol stays legible. The grading you see here is the grading you get in the app.
Not medical advice — educational only. DoseCraft is an information and personal tracking platform. TRT is a prescription therapy; peptide regulatory status varies by jurisdiction. Always work with the licensed clinician managing your testosterone protocol before adding any compound, and order bloodwork through them.